The President and Congress are sounding the alarm on the need for healthcare reform. There are several near-certainties for which pharmaceutical and biotechnology companies must be prepared as they develop forecasts and for the next five or six years.
With the biotech industry reeling from the recession, big drugmakers hold all the cards when it comes to making deals, but picking a winner is still a gamble. Here are 10 to place stakes on.
The sponsors of clinical trials Sunshine Act legislation to improve their physician payment processes, educate the public on the complexity of clinical research and development, and help patients make informed opinions about physicians - bringing true transparency to the financial aspects of discovering new medical treatments.
Sanofi-Aventis is banking that its highly anticipated atrial fibrillation/flutter treatment Multaq will be a huge success. The path to approval has been ridden with a failed trial and a very long review process, but for Sanofi, the wait has been worth it.
Oscient trims 180 sales, marketing, and corporate jobs in the wake of patent expirations, generic competition.
Our second annual Emerging Leadership Awards cast the spotlight on 27 young rising stars most notable for their dedication and contribution to the pharma industry. Here's a closer look at why.
The P4P movement is here. Pharma marketers, it's time to take note.
As it readies submission for a once-weekly diabetes injectable, Amylin announces that it will trim 35 percent of its sales force and put focus on specialty physicians.
Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization.
When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game.
As the US government weighs its options on whether to commission a vaccine for the new H1N1 strain of influenza, pharma companies gear up for a possible epidemic.
In an effort to realign its sales division to reflect the current pharma environment-smaller, faster, better-Johnson & Johnson is trimming its sales force.
A company’s trade secrets and the goodwill it has developed can mean the difference between a blockbuster and a failure. Here’s what you should know and do to properly negotiate post-employment agreements.
Just two months after the purchase of Wyeth, Pfizer breaks its research division into two-one for large molecules and vaccines, and another for small molecules-with Wyeth and Pfizer execs at the helms.
From her start as a physician working in apartheid-era South Africa to the dramatic turnaround and takeover of Millennium, Deborah Dunsire has lived a life that has defied all expectations.
"Best Pharma not Big Pharma" is Merck Serono head Elmar Schnee's business philosophy. He tells Pharm Exec Europe how the Swiss-based company aims to achieve that goal, and points out the current political obstacles.
Now that Vyvanse, Shire's innovative ADD drug, has been approved for adults, the company needs help to quickly roll out a complex message to neurologists. Its solution: a partnership that takes advantage of GSK's CNS muscle.
Compliance woes and stingy insurance providers are walloping the pharmaceutical industry. But now another nuisance is rearing its ugly head, as a high number of patients are ignoring their doctor's orders and dropping their prescriptions on purpose.
After repeated requests for additional study information, the wait has paid off: Lilly was approved to sell its bipolar drug Symbyax for treatment-resistant depression.
Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety-and the regulators who enforce it.
Pfizer is the latest addition to Big Pharma's data disclosure club; the drug giant will be disclosing all physician payments that total more that $500 a year.
GlaxoSmithKline to lay off thousands while embattled KV Pharma drops 40 percent of its work force in latest wave of cuts.
Facing patent expiry for one of its top drugs and an overabundance of sales staff due to recent acquisitions, King announced that it would eliminate 760 jobs.
Convert future revenue into present value with alternative approaches to access capital.
The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most.
